Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New supplement cocktail aims to stop preterm labor

NCT ID NCT07305519

Prevention Sponsor: University of Roma La Sapienza Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a daily supplement containing magnesium, palmitoylethanolamide, high-molecular-weight hyaluronic acid, vitamin B6, and vitamin D can help prevent preterm birth in women at risk. The supplement is given alongside standard vaginal progesterone. The trial will enroll 150 pregnant women with a short cervix (between 15 and 30 mm) and follow them until delivery to see if the combination reduces births before 37 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a combination oral supplement containing magnesium, palmitoylethanolamide, high-molecular-weight hyaluronic acid, vitamin B6, and vitamin D, plus vaginal progesterone
What this could lead to
If it works, this could offer a simple, safe supplement-based way to reduce the risk of preterm birth in women with a short cervix.
What could go wrong
This is a relatively small, early-stage trial (150 participants) and the supplement is added to standard care, so any added benefit may be modest. Results may not apply to all at-risk women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent Singleton pregnancy Maternal age ≥ 18 years Gestational age between 20+0 and 34+0 weeks at enrollment Cervical length between 15 mm and 30 mm measured by transvaginal ultrasound Exclusion Criteria: * Fetal structural anomalies Maternal chronic diseases or pregnancy-related conditions, including diabetes, hypertension, preeclampsia, cardiovascular disease, infections, or autoimmune disorders Multiple gestation Fetal growth abnormalities (estimated fetal weight \<10th or \>90th percentile) Prelabor rupture of membranes (PROM)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Preterm labor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obstetric Labor, Premature Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Preterm labor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Policlinico Umberto I

    RECRUITING

    Rome, RM, 00161, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.